iX Biopharma issues 10 million new shares after warrant exercise

SGX Filings

Apr 08

iX Biopharma Ltd announced that on Apr, 8 2026 it allotted and issued 10.0 million new ordinary shares following the exercise of warrants at S$0.06 per share.

As a result, the company’s issued share capital has risen from 1,038,324,529 to 1,048,324,529 shares.

All 10.0 million shares were issued to Director and substantial shareholder Eddy Lee Yip Hang. The new shares rank pari passu with existing shares and are expected to begin trading on the Singapore Exchange on or around Apr, 10 2026.

To date, 17,565,084 warrants—representing 30.54% of all warrants originally issued—have been exercised. A total of 39,944,395 warrants remain outstanding, each exercisable at S$0.06 until Jul, 18 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1105031047"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1105031047\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1105031047?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-08 18:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1105031047","market":"sg","top_or_hot":-1,"title":"iX Biopharma issues 10 million new shares after warrant exercise","media":"SGX Filings","content":"<p>iX Biopharma Ltd announced that on Apr, 8 2026 it allotted and issued 10.0 million new ordinary shares following the exercise of warrants at S$0.06 per share.</p>\n<p>As a result, the company’s issued share capital has risen from 1,038,324,529 to 1,048,324,529 shares.</p>\n<p>All 10.0 million shares were issued to Director and substantial shareholder Eddy Lee Yip Hang. The new shares rank pari passu with existing shares and are expected to begin trading on the Singapore Exchange on or around Apr, 10 2026.</p>\n<p>To date, 17,565,084 warrants—representing 30.54% of all warrants originally issued—have been exercised. A total of 39,944,395 warrants remain outstanding, each exercisable at S$0.06 until Jul, 18 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>iX Biopharma issues 10 million new shares after warrant exercise</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\niX Biopharma issues 10 million new shares after warrant exercise\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1083912268\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/57d1beae95c40ebe9f2698a436562e39);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">SGX Filings </p>\n<p class=\"h-time\">2026-04-08 18:13</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>iX Biopharma Ltd announced that on Apr, 8 2026 it allotted and issued 10.0 million new ordinary shares following the exercise of warrants at S$0.06 per share.</p>\n<p>As a result, the company’s issued share capital has risen from 1,038,324,529 to 1,048,324,529 shares.</p>\n<p>All 10.0 million shares were issued to Director and substantial shareholder Eddy Lee Yip Hang. The new shares rank pari passu with existing shares and are expected to begin trading on the Singapore Exchange on or around Apr, 10 2026.</p>\n<p>To date, 17,565,084 warrants—representing 30.54% of all warrants originally issued—have been exercised. A total of 39,944,395 warrants remain outstanding, each exercisable at S$0.06 until Jul, 18 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"42C.SI","symbol_name":"IX生物制药","start_time":0,"source_url":"","article_id":"1105031047","we_media_id":"1083912268","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1105031047","pubTimestamp":1775643206,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"SGX Filings","introduction":"Fastest News on SGX Filings ","home_visible":1,"id":"1083912268","head_image":"https://community-static.tradeup.com/news/57d1beae95c40ebe9f2698a436562e39"},"summary":"iX Biopharma Ltd announced that on Apr, 8 2026 it allotted and issued 10.0 million new ordinary shares following the exercise of warrants at S$0.06 per share. As a result, the company’s issued share...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"42C.SI":"IX生物制药"},"translate_title":"iX Biopharma认股权证行使后发行1000万股新股","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"42C.SI":1},"content_text":"iX Biopharma Ltd announced that on Apr, 8 2026 it allotted and issued 10.0 million new ordinary shares following the exercise of warrants at S$0.06 per share.\nAs a result, the company’s issued share capital has risen from 1,038,324,529 to 1,048,324,529 shares.\nAll 10.0 million shares were issued to Director and substantial shareholder Eddy Lee Yip Hang. The new shares rank pari passu with existing shares and are expected to begin trading on the Singapore Exchange on or around Apr, 10 2026.\nTo date, 17,565,084 warrants—representing 30.54% of all warrants originally issued—have been exercised. A total of 39,944,395 warrants remain outstanding, each exercisable at S$0.06 until Jul, 18 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}